Targeting schistosome histone modifying enzymes for drug development

Current Pharmaceutical Design

Volumn 18, Issue 24, 2012, Pages 3567-3578

  Pierce, Raymond J ^a,b,c   Dubois Abdesselem, Florence ^a,b,c   Lancelot, Julien ^a,b,c   Andrade, Luiza ^d   Oliveira, Guilherme ^d  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

^c CNRS   (France)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Drug target; Histone deacetylase; Histone modifying enzyme; Inhibitor; Schistosoma mansoni

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACYLTRANSFERASE INHIBITOR; ANACARDIC ACID; ANTISCHISTOSOMAL AGENT; AZACITIDINE; CINNAMIC ACID DERIVATIVE; CURCUMIN; CYSTEINE DERIVATIVE; ENZYME; GAMMA BUTYROLACTONE DERIVATIVE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; HISTONE MODIFYING ENZYME; HISTONE MODIFYING ENZYME INHIBITOR; HYDROLASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGENASE INHIBITOR; ROMIDEPSIN; SIRTINOL; SIRTUIN; SURFACTIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTHELMINTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE SEQUENCE; GENETIC CODE; GENETIC SCREENING; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN TARGETING; SCHISTOSOMA; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TRANSCRIPTION REGULATION;

EID: 84867542415     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801327248     Document Type: Article

References (115)

1. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005; 365: 1561-9.
2. Fenwick A, Webster JP, Bosque-Oliva E, et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology 2009; 136: 1719-30.
3. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008; 21: 659-67.
4. Fallon PG, Doenhoff, MJ. Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg 1994; 51: 83-8.
5. Cioli D. Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis. 2000; 13: 659-63.
6. Shu-Hua X, Utzinger J, Chollet J, Tanner M. Effect of artemether administered alone or in combination with praziquantel to mice infected with Plasmodium berghei or Schistosoma mansoni or both. Int J Parasitol 2006; 36: 957-64.
7. Manneck T, Braissant O, Ellis W, Keiser J. Schistosoma mansoni: Antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo. Exp Parasitol 2001; 127: 260-9.
8. Keiser J, Chollet J, Xiao SH, et al. Mefloquine: an aminoalcohol with promising antischistosomal properties in mice. PLoS Neg Trop Dis 2009; 3(1): e350.
9. Boissier J, Coslédan F, Rober A, Meunier B. In vitro activities of trioxaquines against Schistosoma mansoni. Antimicrob Agents Chemother 2009; 53: 4903-6.
10. Baard AP, Sommers DK, Honiball PJ, Fourie ED, Du Toit LE. Preliminary results in human schistosomiasis with Ro11-3128. S Afr Med J 1979; 55: 617-8.
11. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008; 14: 407-12.
12. Dissous C, Grevelding CG. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? Trends Parasitol 2011; 27: 59-66.
13. Beckmann S, Grevelding CG. Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro. Int J Parasitol 2010; 40: 521-6.
14. Berriman M, Haas B, Loverde PT, et al. The Genome of the blood fluke Schistosoma mansoni. Nature 2009; 462: 352-8.
15. The Schistosoma japonicum Genome Sequencing and Functional Analysis Consortium. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 2009; 460: 345-52.
16. Thompson DP, Morrison DD, Pax RA, Bennett JL. Changes in glucose metabolism and cyanide sensitivity in Schistosoma mansoni during development. Mol Biochem Parasitol 1984; 13: 39-51.
17. Skelly PJ, Shoemaker CB. A molecular genetic study of the variations in metabolic function during schistosome development. Mem Inst Oswaldo Cruz 1995; 90: 281-4.
18. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-37.
19. Vaidya AB, Mather MW. Mitochondrial evolution and functions in malaria parasites. Ann Rev Microbiol 2009; 63: 249-67.
20. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069-78.
21. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
22. Jeunwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-80.
23. Fantappié MR, Pereira Gimba ER, Rumjanek FD. Lack of DNA methylation in Schistosoma mansoni. Exp Parasitol. 2001; 98: 162-6.
24. Geyer KK, Rodríguez López CM, Chalmers IW, et al. Cytosine methylation regulates oviposition in the pathogenic blood fluke Schistosoma mansoni. Nat Commun. 2011; 2: 424. doi: 10.1038/ncomms1433.
25. Sterner DE, Berger SL. Acetylation of histones and transcriptionrelated factors. Microbiol Mol Biol Rev 2000; 64: 435-59.
26. de Moraes Maciel R, de Silva Dutra DL, Rumjanek FD, Juliano L, Juliano MA, Fantappié MR 2004. Schistosoma mansoni histone acetyltransferase GCN5: linking histone acetylation to gene activation. Mol Biochem Parasitol 2004; 133: 131-5.
27. de Moraes Maciel R, da Costa RF, de Oliveira FM, Rumjanek FD, Fantappié MR. Protein acetylation sites mediated by Schistosoma mansoni GCN5. Biochem Biophys Res Commun 2008; 370: 53-6.
28. Bertin B Oger F, Cornette J, et al. Schistosoma mansoni CBP/p300 has a conserved domain structure and interacts functionally with the nuclear receptor SmFtz-F1. Mol Biochem Parasitol 2006; 146: 180-91.
29. Fantappié MR, Bastos de Oliveira FM, de Moraes Maciel R, Rumjanek FD, Wu W, Loverde PT. Cloning of SmNCoA-62, a novel nuclear receptor co-activator from Schistosoma mansoni: assembly of a complex with a SmRXR1/SmNR1 heterodimer, SmGCN5 and SmCBP1. Int J Parasitol 2008; 38: 1133-47.
30. Gregoretti IV, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
31. Oger F, Dubois F, Caby S, Noël C, Cornette J, Bertin B, Capron M, Pierce RJ 2008. The Schistosoma mansoni class I histone deacetylases. Biochem Biophys Res Commun 377: 1079-1084.
32. Brunmeir R, Lagger S, Seiser C. Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation. Int J Dev Biol 2009; 53: 275-89.
33. Hu E, Chen Z, Fredrickson T, et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000; 275: 15254-64.
34. Haigis MC Mostoslavsky R, Haigis KM, et al. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 2006; 126: 941-54.
35. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000; 273: 793-8.
36. Michisita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and non-conserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-35.
37. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-48.
38. Daitoku H, Hatta M, Matsuzaki H, et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci USA 2004; 101: 10042-7.
39. Nakai K, Horton P. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci. 1999; 24: 34-6.
40. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005; 6: 838-49.
41. Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Lett 2011; 585: 2024-31.
42. Qian C, Zhou MM. SET domain protein lysine methyltranferases: structure, specificity and catalysis. Cell Mol Life Sci 2006; 63: 2755-63.
43. Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev 2011; 25: 1345-58.
44. Nimura K, Ura K, Kaneda Y. Histone methyltransferases: regulation of transcription and contribution to human disease. J Mol Med 2010; 88: 1213-20.
45. Jelinic P, Stehle JC, Shaw P. The testis-specific factor CTCF2 cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol 2006; 4(11): e355.
46. Choi S, Jung CR, Kim JY, Im DS. PRMT3 inhibits ubiquitination of ribosomal protein S2 and together forms an active enzyme complex. Biochim. Biophys. Acta 2008; 1780: 1062-1069.
47. Shi X, Kachirskaia I, Yamaguchi H, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007 Aug 17; 27(4): 636-46.
48. Anand R, Marmorstein R. Structure and mechanism of lysinespecific demethylase enzymes. J Biol Chem 2007; 282: 35425-9.
49. Agger K, Cloos PA, Christensen J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007; 449: 731-4.
50. Ezhkova E, Lien WH, Stokes N, Pasolli HA, Silva JM, Fuchs E. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 2011; 25: 485-98.
51. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral corinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109: 31-9.
52. Wagner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 2010; 1: 117-36.
53. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Disc 2006; 5: 769-84.
54. Andrews KT, Walduck A, Kelso MJ, Fairlie DP, Saul A, Parsons PG. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int J Parasitol 2000; 30: 761-8.
55. Andrews KT, Tran TN, Lucke AJ, et al. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob Agents Chemother 2008; 52: 1454-61.
56. Wheatley NC, Andrews KT, Tran TL, Lucke AJ, Reid RC, Fairlie DP. Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components. Bioorg Med Chem Lett 2010; 20: 7080-4.
57. Strobl JS Cassell M, Mitchell SM, Reilly CM, Lindsay DS. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. J Parasitol 2007; 93: 694-700.
58. Murray PJ Kranz M, Ladlow M, et al. The synthesis of cyclic tetrapeptoid analogues of the antiprotozool natural product apicidin. Bioorg Med Chem Lett 2001; 1: 733-736.
59. Azzi A, Cosseau C, Grunau C. Schistosoma mansoni: developmental arrest of miracidia treated with histone deacetylase inhibitors. Exp Parasitol 2009; 121: 288-91.
60. Dubois F, Caby S, Oger F, et al. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni, Mol Biochem Parasitol 2009; 168: 7-15.
61. Heltweg B Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-77.
62. Neugebauer RC, Uchiechowska U, Meier R, et al. Structureactivity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem 2008; 51: 1203-13.
63. Uciechowska U Schemies J, Neugebauer RC, et al. Thiobarbiturates as Sirtuin Inhibitors: Virtual Screening, Free-Energy Calculations, and Biological Testing. ChemMedChem 2008; 3: 1965-76.
64. Merrick CJ, Duraisingh MT. Plasmodium falciparum Sir2: an unusual sirtuin with dual histone deacetylase and ADP- ribosyltransferase activity. Eukaryot Cell 2007; 6: 2081-91.
65. Prusty D Mehra P, Srivastava S, et al. Nicotinamide inhibits Plasmodium falciprum Sir2 activity in vitro and parasite growth. FEMS Microbiol Lett 2008; 282: 266-72.
66. Chakrabarty SP Saikumari YK, Bopanna MP, Balaram H. Biochemical characterization of Plasmodium falciparum Sir2, a NAD+-dependent deacetylase. Mol Biochem Parasitol 2008; 158: 139-51.
67. Chakrabarty SP, Ramapanicker R, Mishra R, Chandrasekaran S, Balaram H. Development and characterization of lysine based tripeptide analogues as inhibitors of Sir2 activity. Bioorg Med Chem 2009; 17: 8060-72.
68. Vergnes B, Vanhille L, Ouaissi A, Sereno D.Stage-specific antileishmanial activity of an inhibitor of Sir2 histone deacetylase. Acta Trop 2005; 94: 107-15.
69. Kadam RU, Tavares J, Kiran VM, Cordeiro A, Ouaissi A, Roy N. Structure function analysis of Leishmania sirtuin: an ensemble of in silico and biochemical studies. Chem Biol Drug Des 2008; 71: 501-6.
70. Tavares J, Ouaissi A, Kong Thoo Lin P, et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. ChemMedChem 2010; 5: 140-7.
71. Stimson L, Rowlands MG, Newbatt YM, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005; 4: 1521-32.
72. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279: 51163-71.
73. Cui L, Miao J, Furuya T, et al. Histone acetyltransferase inhibitor anacardic acid causes changes in global gene expression during in vitro Plasmodium falciparum development. Eukaryot Cell 2008; 7: 1200-10.
74. Smith AT, Livingston MR, Mai A, Filetici P, Queener SF, Sullivan WJ Jr. Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii. Antimicrob Agents Chemother. 2007; 51: 1109-11.
75. Spannhof A, Hauser AT, Heinke R, Sipple W, Jung M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 2009; 4: 1568-82.
76. Lohse B, Kristensen JL, Kristensen LH, et al. Inhibitors of histone demethylases. Bioorg Med Chem 2011; 19: 3625-36.
77. Spannhoff A, Sippl W, Jung M. Cancer treatment of the future: inhibitors of histone methyltransferases. Int J Biochem Cell Biol 2009; 41: 4-11.
78. Tang J, Frankel A, Cook RJ, et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 2000; 275: 7723-30.
79. Bissinger EM, Heinke R, Spannhoff A, et al. Acyl derivatives of paminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem. 2011; 19: 3717-31.
80. Obianyo O, Causey CP, Osborne TC, et al. A chloroacetamidinebased inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation. ChemBioChem 2010; 11: 1219-23.
81. Kubicek S, O'Sullivan RJ, August EM, et al. Reversal of H3K9me2 by a small molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007; 25: 473-81.
82. Kondo Y, Shen L, Ahmed S, et al. Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLOS One 2008; 3; e2037.
83. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53-65.
84. Zhou J, Bi C, Cheong LL, et al. The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production and targets leukaemia cells in AML. Blood 2011; 118: 2830-9.
85. Schmidt AM, McCafferty DG. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007; 46: 4408-16.
86. Wang J, Lu F, Ren Q, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011; epub ahead of print.
87. Singh MM, Manton CA, Bhat KP, et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro Oncol 2011; 13: 894-903.
88. Pierce RJ, Dubois-Abdesselem F, Caby S, et al. Chromatin regulation in schistosomes and histone-modifying enzymes as drug targets. Mem. Inst. Oswaldo Cruz, 2011; 106: 794-801.
89. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011; 10: 507-19.
90. Rask-Andersen M, Almen MS, Schiöth HB. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011; 10: 579-90.
91. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 32: 5459-68.
92. Minucci S, Plicci PG. Retinoid receptors in health and disease: coregulators and the chromatin connection. Semin Cell Dev Biol 1999; 10: 215-25.
93. Minucci S, Nervi C, Lo Coco F, et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001; 20: 3110-5.
94. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125: 1045-52.
95. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 673-8.
96. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4: 549-51.
97. Vannini A, Volpari C, Filocamo G, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004; 101: 15064-9.
98. Oehme I, Deubzer HE, Wegener D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009; 15: 91-9.
99. Park SY, Jun JA, Jeong KJ, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 2011; 25: 1677-81.
100. Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM. Design and evaluation of "Linkerless" hydroxamic acids as selective HDAC8 inhibitors. BioorgMed Chem Lett 2007; 17: 2874-8.
101. Zhao Y, Tan J, Zhuang L Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apotosis induction through activation of pro-apoptotic protein Bim. Proc Natl Acad Sci USA 2005; 102: 16090-5.
102. Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ 2006; 13: 129-140.
103. Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q 2006. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem 281: 10508-15.
104. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76.
105. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukaemia cells. Nat Med 2005; 11: 77-84.
106. Lee EF, Clarke OB, Evangelista M, et al. Discovery and molecular characterization of a Bcl-2-regulated cell death pathway in schistosomes. Proc Natl Acad Sci USA 2011; 108: 6999-7003.
107. Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 2010; 16: 528-36.
108. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612-26.
109. Kurash JK, Lei H, Shen Q, et al. Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell 2008; 29: 392-400.
110. Van Leeuwen I, Lain S. Sirtuins and p53. Adv Cancer Res 2009; 102: 171-95.
111. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-48.
112. Fortson WS, Kayarthodi S, Fujimara Y, et al. Histone deacetylase inhibitors, valproic acid and trichostatin A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011; 39: 111-9.
113. Ramsay MR, He L, Forster N, Ory B, Ellisen LW. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res 2011; 71: 4373-9.
114. Rutkowski R, Hofmann K, Gartner A. Phylogeny and function of the invertebrate p53 superfamily. Cold Spring Harb Perspect Biol 2010; 2: a001131.
115. Liu X, Wang D, Zhao Y, et al. Methyltransferase Set7/9 regulates p53 activity by interacting with sirtuin 1 (SIRT1). Proc Natl Acad Sci USA 2011; 108: 1925-30.